• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Apollo Medical Holdings, Inc. Reports Second Quarter 2023 Results

    8/7/23 5:17:00 PM ET
    $AMEH
    Professional Services
    Consumer Discretionary
    Get the next $AMEH alert in real time by email

    Company to Host Conference Call on Monday, August 7, 2023, at 2:30 p.m. PT/5:30 p.m. ET

    ALHAMBRA, Calif., Aug. 7, 2023 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced its consolidated financial results for the second quarter ended June 30, 2023.

    ameh logo (PRNewsfoto/Apollo Medical Holdings, Inc.)

    Brandon Sim, Co-Chief Executive Officer of ApolloMed, stated, "Our strong second quarter performance reflects the sustained momentum and scalability of the ApolloMed model, with revenue up 29%, net income attributable to ApolloMed up 10%, and adjusted EBITDA up 44% compared to a year ago. We remain focused on our three key operational goals of growing our membership, empowering our providers, and improving patient outcomes, and we continue to drive meaningful progress in all three areas in California, Nevada, Texas, and beyond."

    "We want to thank our providers and teammates for their hard work and dedication that resulted in our continued solid financial performance in the second quarter of 2023 and our confidence in reiterating our previously provided guidance for full-year 2023."

    Financial Highlights for Second Quarter Ended June 30, 2023:

    All comparisons are to the quarter ended June 30, 2022 unless otherwise stated.

    • Total revenue of $348.2 million, up 29% from $269.7 million
    • Care Partners revenue of $325.2 million, up 32% from $247.3 million
    • Net income attributable to ApolloMed of $13.2 million, up 10% from $12.0 million
    • Adjusted EBITDA of $35.8 million, up 44% from $24.9 million

    Financial Highlights for Six Months Ended June 30, 2023:

    All comparisons are to the six months ended June 30, 2022 unless otherwise stated.

    • Total revenue of $685.5 million, up 29% from $533.0 million
    • Care Partners revenue of $639.9 million, up 31% from $488.6 million
    • Net income attributable to ApolloMed of $26.3 million, up 2% from $25.7 million
    • Adjusted EBITDA of $65.6 million, up 11% from $59.3 million

    Recent Operating Highlights Subsequent to the End of the Second Quarter:

    • On July 12, 2023, the Company announced that it had entered into a definitive agreement to acquire assets of Texas Independent Providers, LLC ("TIP"), a value-based provider network with over 120 primary care providers that is expected to be an anchor for our high-quality Care Partners business in Houston. Through this transaction, ApolloMed intends to empower TIP's provider network to deliver best-in-class clinical outcomes and to improve the healthcare experience for patients. This transaction is expected to close in the third quarter of 2023, and TIP's providers are expected to be onboarded onto ApolloMed's Care Enablement platform by the end of 2023.



    • On July 27, 2023, the Company formed a long-term partnership with a primary care group operating in California with over 50 providers. The group is expected to be onboarded onto ApolloMed's Care Enablement platform by September 1, 2023.



    • On July 31, 2023, the Company announced a partnership with IntraCare, an operator of a value-based primary care provider network with over 425 providers located in Dallas, Fort Worth, El Paso, Austin, and Oklahoma City. Through this partnership, IntraCare's providers are expected to join ApolloMed's high-quality Care Partners business in these regions and onboarded onto ApolloMed's Care Enablement platform by the end of 2023. In addition, ApolloMed will lend IntraCare a $25 million senior secured convertible promissory note maturing in 2028 to further IntraCare's mission and growth.

    Segment Results for the Second Quarter Ended June 30, 2023:



    Three Months Ended June 30, 2023



    Care

    Enablement



    Care

    Partners



    Care

    Delivery



    Other



    Intersegment

    Elimination



    Corporate

    Costs



    Consolidated

    Total

    Total revenues

    $         34,975



    $       325,246



    $        26,718



    $          157



    $         (38,887)



    $                   —



    $           348,209

    % change vs. prior year quarter

    18 %



    32 %



    14 %



    —



    —



    —



    29 %





























    Cost of services

    15,162



    292,119



    22,523



    70



    (36,998)



    —



    292,876

    General and administrative(1)

    12,175



    5,298



    3,626



    926



    (2,933)



    9,212



    28,304

    Total expenses

    27,337



    297,417



    26,149



    996



    (39,931)



    9,212



    321,180





























    Income (loss) from operations

    $           7,638



    $         27,829



    $             569



    $        (839)



    $             1,044

    (2)

    $            (9,212)



    $             27,029

    % change vs. prior year quarter

    4 %



    250 %



    (83 %)



    —



    —



    —



    76 %



    (1) Balance includes general and administrative expenses and depreciation and amortization.

    (2) Income from operations for the intersegment elimination represents rental income from segments renting from other segments. Rental income is presented within other income which is not presented in the table.

    Guidance:

    ApolloMed is reiterating the following guidance for total revenue, net income, EBITDA, Adjusted EBITDA, and EPS - diluted, based on the Company's existing business, current view of existing market conditions and assumptions for the year ending December 31, 2023.

    ($ in millions)

    2023 Guidance Range



    Low



    High

    Total revenue

    $              1,300.0



    $              1,500.0

    Net income

    $                   49.5



    $                   71.5

    EBITDA

    $                   89.5



    $                 129.5

    Adjusted EBITDA

    $                 120.0



    $                 160.0

    EPS – diluted

    $                   0.95



    $                   1.20

    See "Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA" and "Use of Non-GAAP Financial Measures" below for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See "Forward-Looking Statements" below for additional information.

    Conference Call and Webcast Information:

    ApolloMed will host a conference call at 2:30 p.m. PT/5:30 p.m. ET today (Monday, August 7, 2023), during which management will discuss the results of the second quarter ended June 30, 2023. To participate in the conference call, please use the following dial-in numbers about 5 minutes prior to the scheduled conference call time:

    U.S. & Canada (Toll-Free):        +1 (877) 858-9810

    International (Toll):                     +1 (201) 689-8517

    The conference call can also be accessed via webcast at: https://event.choruscall.com/mediaframe/webcast.html?webcastid=SC6cioUx.

    An accompanying slide presentation will be available in PDF format on the "IR Calendar" page of the Company's website (https://www.apollomed.net/investors/news-events/ir-calendar) after issuance of the earnings release and will be furnished as an exhibit to ApolloMed's current report on Form 8-K to be filed with the SEC, accessible at www.sec.gov.

    Those who are unable to attend the live conference call may access the recording at the above webcast link, which will be made available shortly after the conclusion of the call.

    Note About Consolidated Entities

    The Company consolidates entities in which it has a controlling financial interest. The Company consolidates subsidiaries in which it holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third party equity ownership interests in the Company's consolidated entities (including certain VIEs). The amount of net income attributable to noncontrolling interests is disclosed in the Company's consolidated statements of income.

    Note About Stockholders' Equity, Certain Treasury Stock and Earnings Per Share

    As of the date of this press release, 140,954 holdback shares have not been issued to certain former shareholders of the Company's subsidiary, Network Medical Management, Inc. ("NMM"), who were NMM shareholders at the time of closing of the merger, as they have yet to submit properly completed letters of transmittal to ApolloMed in order to receive their pro rata portion of ApolloMed's common stock and warrants as contemplated under that certain Agreement and Plan of Merger, dated December 21, 2016, among ApolloMed, NMM, Apollo Acquisition Corp. ("Merger Subsidiary") and Kenneth Sim, M.D., as amended, pursuant to which Merger Subsidiary merged with and into NMM, with NMM as the surviving corporation. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the merger. The Company's consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and ApolloMed is legally obligated to issue these shares in connection with the merger.

    Shares of ApolloMed's common stock owned by Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California ("APC"), a VIE of the Company, are legally issued and outstanding but excluded from shares of common stock outstanding in the Company's consolidated financial statements, as such shares are treated as treasury shares for accounting purposes. Such shares, therefore, are not included in the number of shares of common stock outstanding used to calculate the Company's earnings per share.

    About Apollo Medical Holdings, Inc.

    ApolloMed is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver outcomes-based medical care to patients in a cost-effective manner.

    Headquartered in Alhambra, California, ApolloMed's subsidiaries and affiliates include management services organizations (MSOs), affiliated independent practice associations (IPAs), and entities participating in the Centers for Medicare & Medicaid Services Innovation Center (CMMI) innovation models. For more information, please visit www.apollomed.net.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements about the Company's guidance for the year ending December 31, 2023, ability to meet operational goals, ability to meet expectations in deployment of care coordination and management capabilities, ability to decrease cost of care while improving quality and outcomes, ability to deliver sustainable revenue and EBITDA growth as well as long-term value, ability to respond to the changing environment, and successful implementation of strategic growth plans, acquisition strategy, and merger integration efforts. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company's reports to the SEC, including, without limitation the risk factors discussed in the Company's Annual Report on Form 10-K/A for the year ended December 31, 2022, and any subsequent quarterly reports on Form 10-Q. Any forward-looking statement made by the Company in this release speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

    Restatement

    In connection with a review of the Company's income tax filing structure, the Company identified unintentional errors in its accounting for the income tax effects of certain intercompany dividends and certain net operating losses, which resulted in an understatement of income tax expense in prior periods and also had an impact on purchase accounting (goodwill) as a portion of the net operating losses affected by the errors pertained to acquisitions in prior periods. As a result of the errors, the Company has restated the December 31, 2022 consolidated balance sheet and the consolidated statement of operations for each of the three and six months ended June 30, 2022. 

    FOR MORE INFORMATION, PLEASE CONTACT:

    Investor Relations

    (626) 943-6491

    [email protected]

    Carolyne Sohn, The Equity Group

    (408) 538-4577

    csohn@equityny.com

    APOLLO MEDICAL HOLDINGS, INC.

     CONSOLIDATED BALANCE SHEETS

    (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)

    (UNAUDITED)















    June 30,

    2023



    December 31,

    2022









    (Restated)

    Assets



















    Current assets









    Cash and cash equivalents



    $           293,921



    $           288,027

    Restricted cash



    345



    —

    Investments in marketable securities



    3,789



    5,567

    Receivables, net



    66,927



    49,631

    Receivables, net – related parties



    82,820



    65,147

    Other receivables



    1,201



    1,834

    Prepaid expenses and other current assets



    15,088



    14,798

    Loans receivable



    973



    996

    Loan receivable – related party



    —



    2,125











    Total current assets



    465,064



    428,125











    Non-current assets









    Land, property, and equipment, net



    123,859



    108,536

    Intangible assets, net



    74,421



    76,861

    Goodwill



    274,029



    269,053

    Income taxes receivable, non-current



    15,943



    15,943

    Investments in other entities – equity method



    45,831



    40,299

    Investments in privately held entities



    2,896



    896

    Operating lease right-of-use assets



    17,905



    20,444

    Other assets



    7,229



    6,056











    Total non-current assets



    562,113



    538,088











    Total assets(1)



    $        1,027,177



    $           966,213











    Liabilities, mezzanine equity and equity



















    Current liabilities



















    Accounts payable and accrued expenses



    $             49,904



    $             49,562

    Fiduciary accounts payable



    8,603



    8,065

    Medical liabilities



    100,047



    81,255

    Income taxes payable



    19,628



    4,279

    Dividend payable



    638



    664

    Finance lease liabilities



    591



    594

    Operating lease liabilities



    3,027



    3,572

    Current portion of long-term debt



    2,630



    619

    Total current liabilities



    185,068



    148,610











    Non-current liabilities









    Deferred tax liability



    12,383



    14,217

    Finance lease liabilities, net of current portion



    1,078



    1,275

    Operating lease liabilities, net of current portion



    17,852



    19,915

    Long-term debt, net of current portion and deferred financing costs



    205,136



    203,389

    Other long-term liabilities



    21,383



    20,260











    Total non-current liabilities



    257,832



    259,056











    Total liabilities(1)



    442,900



    407,666











    Mezzanine equity









    Non-controlling interest in Allied Physicians of California, a Professional Medical

    Corporation



    14,523



    14,237











    Stockholders' equity









    Series A Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of

    Series B Preferred stock); 1,111,111 issued and zero outstanding



    —



    —

    Series B Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of

    Series A Preferred stock); 555,555 issued and zero outstanding



    —



    —

    Common stock, $0.001 par value per share; 100,000,000 shares authorized,

    46,553,517 and 46,575,699 shares issued and outstanding, excluding 10,569,340 and

    10,299,259 treasury shares, at June 30, 2023, and December 31, 2022, respectively



    47



    47

    Additional paid-in capital



    357,246



    360,097

    Retained earnings



    208,720



    182,417

       Total stockholders' equity



    566,013



    542,561











    Non-controlling interest



    3,741



    1,749











    Total equity



    569,754



    544,310











    Total liabilities, mezzanine equity and equity



    $       1,027,177



    $           966,213



    (1) The Company's consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities ("VIEs"). The consolidated balance sheets include total assets that can be used only to settle obligations of the Company's consolidated VIEs totaling $520.8 million and $515.1 million as of June 30, 2023 and December 31, 2022, respectively, and total liabilities of the Company's consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $145.8 million and $133.5 million as of June 30, 2023 and December 31, 2022, respectively. The VIE balances do not include $325.5 million of investment in affiliates and $5.4 million of amounts due to affiliates as of June 30, 2023 and $304.8 million of investment in affiliates and $30.3 million of amounts due from affiliates as of December 31, 2022 as these are eliminated upon consolidation and not presented within the consolidated balance sheets.

     

    APOLLO MEDICAL HOLDINGS, INC.

    CONSOLIDATED STATEMENTS OF OPERATIONS

    (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)

    (UNAUDITED)



















    Three Months Ended

    June 30,



    Six Months Ended

    June 30,





    2023



    2022

    (restated)



    2023



    2022

    (restated)

    Revenue

















    Capitation, net



    $      300,549



    $      227,623



    $      600,753



    $      449,682

    Risk pool settlements and incentives



    20,121



    18,793



    33,583



    36,868

    Management fee income



    12,493



    9,984



    22,389



    20,457

    Fee-for-service, net



    13,262



    11,740



    25,324



    22,835

    Other revenue



    1,784



    1,557



    3,404



    3,112



















    Total revenue



    348,209



    269,697



    685,453



    532,954



















    Operating expenses

















    Cost of services, excluding depreciation and amortization



    292,876



    230,070



    582,273



    450,798

    General and administrative expenses



    24,056



    19,894



    45,236



    31,837

    Depreciation and amortization



    4,248



    4,351



    8,541



    8,725



















    Total expenses



    321,180



    254,315



    636,050



    491,360



















    Income from operations



    27,029



    15,382



    49,403



    41,594



















    Other income (expense)

















    Income from equity method investments



    2,723



    1,512



    5,207



    2,945

    Interest expense



    (3,632)



    (1,854)



    (6,901)



    (2,927)

    Interest income



    3,327



    421



    6,335



    467

    Unrealized gain (loss) on investments



    859



    (1,866)



    (5,533)



    (10,829)

    Other income



    1,185



    3,034



    2,389



    3,647



















    Total other income (expense), net



    4,462



    1,247



    1,497



    (6,697)



















    Income before provision for income taxes



    31,491



    16,629



    50,900



    34,897



















    Provision for income taxes



    14,009



    5,352



    20,930



    12,170



















    Net income



    17,482



    11,277



    29,970



    22,727



















    Net income (loss) attributable to non-controlling interest



    4,312



    (673)



    3,668



    (2,987)



















    Net income attributable to Apollo Medical Holdings, Inc.



    $        13,170



    $        11,950



    $        26,302



    $        25,714



















    Earnings per share – basic



    $             0.28



    $             0.27



    $             0.57



    $             0.57



















    Earnings per share – diluted



    $             0.28



    $             0.26



    $             0.56



    $             0.56

     

    Reconciliation of Net Income to EBITDA and Adjusted EBITDA



































    Three Months Ended June 30,



    Six Months Ended June 30,



    (in thousands)



    2023



    2022 (restated)



    2023 (restated)



    2022 (restated)























    Net income



    $           17,482



    $           11,277



    $           29,970



    $           22,727



    Interest expense



    3,632



    1,854



    6,901



    2,927



    Interest income



    (3,327)



    (421)



    (6,335)



    (467)



    Provision for income taxes



    14,009



    5,352



    20,930



    12,170



    Depreciation and amortization



    4,248



    4,351



    8,541



    8,725



    EBITDA



    36,044



    22,413



    60,007



    46,082























    Income from equity method investments



    (297)



    (180)



    (546)



    (328)



    Other, net



    (1,618)

    (1)

    —



    (216)

    (1)

    —



    Stock-based compensation



    4,213



    3,920



    7,658



    6,975



    APC excluded assets costs



    (2,570)



    (1,247)



    (1,304)



    6,537



    Adjusted EBITDA



    $           35,772



    $           24,906

    (2)

    $           65,599



    $           59,266

    (2)



    (1) Other, net for the three and six months ended June 30, 2023 relates to non-cash changes in the fair value of our financing obligation to purchase the remaining equity interests, changes in the fair value of our contingent liabilities, and changes in the fair value of the Company's Collar Agreement.

    (2) Adjusted EBITDA under the historical method for the three and six months ended June 30, 2022 was $36.9 million and $75.1 million, respectively. See "Use of Non-GAAP Financial Measures" below for additional information on change of methodology.

     

    Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA











    2023 Guidance Range

    (in thousands)

    Low



    High

    Net income

    $             49,500



    $             71,500

    Interest expense

    1,000



    1,000

    Provision for income taxes

    23,000



    38,000

    Depreciation and amortization

    16,000



    19,000

    EBITDA

    89,500



    129,500









    Loss (income) from equity method investments

    (750)



    (750)

    Other, net

    3,250



    3,250

    Stock-based compensation

    16,000



    16,000

    APC excluded assets costs

    12,000



    12,000

    Adjusted EBITDA

    $           120,000



    $           160,000

     

    Use of Non-GAAP Financial Measures

    This earnings release contains the non-GAAP financial measures EBITDA and Adjusted EBITDA, of which the most directly comparable financial measure presented in accordance with U.S. generally accepted accounting principles ("GAAP") is net income. These measures are not in accordance with, or alternatives to GAAP, and may be calculated differently from similar non-GAAP financial measures used by other companies. The Company uses Adjusted EBITDA as a supplemental performance measure of our operations, for financial and operational decision-making, and as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization, excluding income or loss from equity method investments, non-recurring and non-cash transactions, stock-based compensation, and APC excluded assets costs. Beginning in the third quarter ended September 30, 2022, the Company has revised the calculation for Adjusted EBITDA to exclude provider bonus payments and losses from recently acquired IPAs, which it believes to be more reflective of its business.

    The Company believes the presentation of these non-GAAP financial measures provides investors with relevant and useful information, as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core or non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of the Company's ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources, and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. To the extent this release contains historical or future non-GAAP financial measures, the Company has provided corresponding GAAP financial measures for comparative purposes. The reconciliation between certain GAAP and non-GAAP measures is provided above.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/apollo-medical-holdings-inc-reports-second-quarter-2023-results-301895050.html

    SOURCE Apollo Medical Holdings, Inc.

    Get the next $AMEH alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AMEH

    DatePrice TargetRatingAnalyst
    2/22/2024$44.00 → $55.00Neutral → Buy
    BofA Securities
    1/24/2024$45.00Buy
    Stifel
    12/22/2023$41.00Hold
    Truist
    10/17/2023$45.00Buy
    BTIG Research
    4/12/2023$44.00Neutral
    BofA Securities
    12/19/2022$40.00Buy
    Lake Street
    9/21/2022Outperform
    William Blair
    1/11/2022$93.00Buy
    Colliers Securities
    More analyst ratings

    $AMEH
    SEC Filings

    See more
    • Apollo Medical Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

      8-K - Astrana Health, Inc. (0001083446) (Filer)

      2/29/24 6:03:30 AM ET
      $AMEH
      Professional Services
      Consumer Discretionary
    • Apollo Medical Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Astrana Health, Inc. (0001083446) (Filer)

      2/27/24 4:19:15 PM ET
      $AMEH
      Professional Services
      Consumer Discretionary
    • Apollo Medical Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Astrana Health, Inc. (0001083446) (Filer)

      2/26/24 6:04:01 AM ET
      $AMEH
      Professional Services
      Consumer Discretionary

    $AMEH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Apollo Medical upgraded by BofA Securities with a new price target

      BofA Securities upgraded Apollo Medical from Neutral to Buy and set a new price target of $55.00 from $44.00 previously

      2/22/24 9:10:05 AM ET
      $AMEH
      Professional Services
      Consumer Discretionary
    • Stifel initiated coverage on Apollo Medical with a new price target

      Stifel initiated coverage of Apollo Medical with a rating of Buy and set a new price target of $45.00

      1/24/24 6:57:05 AM ET
      $AMEH
      Professional Services
      Consumer Discretionary
    • Truist initiated coverage on Apollo Medical with a new price target

      Truist initiated coverage of Apollo Medical with a rating of Hold and set a new price target of $41.00

      12/22/23 7:19:49 AM ET
      $AMEH
      Professional Services
      Consumer Discretionary

    $AMEH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Apollo Medical Holdings, Inc. Becomes Astrana Health, Inc.

      ALHAMBRA, Calif., Feb. 22, 2024 /PRNewswire/ -- Apollo Medical Holdings, Inc.("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:AMEH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, announced today it will formally change its name from Apollo Medical Holdings, Inc. ("ApolloMed") to Astrana Health, Inc. ("Astrana Health"). As previously announced, the Company will begin trading under the ticker symbol "ASTH." Both changes will take effect February 26, 2024.

      2/22/24 8:00:00 AM ET
      $AMEH
      Professional Services
      Consumer Discretionary
    • Apollo Medical Holdings, Inc. Schedules 2023 Fourth Quarter and Full Year Financial Results Release and Conference Call

      ALHAMBRA, Calif., Jan. 31, 2024 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:AMEH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2023, after the close of the stock market on Tuesday, February 27, 2024. The Company will discuss those results on a conference call at 2:30 p.m. PT/5:30 p.m. ET that same day.

      1/31/24 8:00:00 AM ET
      $AMEH
      Professional Services
      Consumer Discretionary
    • ApolloMed and BASS Medical Group to Forge a Value-Based Healthcare Partnership

      ALHAMBRA, Calif., Jan. 29, 2024 /PRNewswire/ -- Apollo Medical Holdings, Inc.("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:AMEH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced a strategic long-term partnership with BASS Medical Group, one of the largest multi-specialty medical groups in the Greater San Francisco Bay Area. The partnership will bolster BASS Medical Group's value-based care and operational infra

      1/29/24 8:00:00 AM ET
      $AMEH
      Professional Services
      Consumer Discretionary

    $AMEH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Apollo Medical Holdings Inc. (Amendment)

      SC 13G/A - Apollo Medical Holdings, Inc. (0001083446) (Subject)

      2/13/24 4:58:57 PM ET
      $AMEH
      Professional Services
      Consumer Discretionary
    • SEC Form SC 13D/A filed by Apollo Medical Holdings Inc. (Amendment)

      SC 13D/A - Apollo Medical Holdings, Inc. (0001083446) (Subject)

      11/17/23 4:15:14 PM ET
      $AMEH
      Professional Services
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Apollo Medical Holdings Inc. (Amendment)

      SC 13G/A - Apollo Medical Holdings, Inc. (0001083446) (Subject)

      2/9/23 11:07:39 AM ET
      $AMEH
      Professional Services
      Consumer Discretionary

    $AMEH
    Financials

    Live finance-specific insights

    See more
    • Apollo Medical Holdings, Inc. Schedules 2023 Fourth Quarter and Full Year Financial Results Release and Conference Call

      ALHAMBRA, Calif., Jan. 31, 2024 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:AMEH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2023, after the close of the stock market on Tuesday, February 27, 2024. The Company will discuss those results on a conference call at 2:30 p.m. PT/5:30 p.m. ET that same day.

      1/31/24 8:00:00 AM ET
      $AMEH
      Professional Services
      Consumer Discretionary
    • Apollo Medical Holdings, Inc. Reports Second Quarter 2023 Results

      Company to Host Conference Call on Monday, August 7, 2023, at 2:30 p.m. PT/5:30 p.m. ET ALHAMBRA, Calif., Aug. 7, 2023 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced its consolidated financial results for the second quarter ended June 30, 2023. Brandon Sim, Co-Chief Executive Officer of ApolloMed, stated, "Our strong

      8/7/23 5:17:00 PM ET
      $AMEH
      Professional Services
      Consumer Discretionary
    • Apollo Medical Holdings, Inc. Schedules 2023 Second Quarter Financial Results Release and Conference Call

      ALHAMBRA, Calif., July 28, 2023 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced that it will release financial results for the second quarter ended June 30, 2023, after the close of the stock market on Monday, August 7, 2023. The Company will discuss those results in a conference call at 2:30 p.m. PT/5:30 p.m. ET that same day.

      7/28/23 8:05:00 AM ET
      $AMEH
      Professional Services
      Consumer Discretionary

    $AMEH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Kumar Dinesh M. was granted 150,395 shares (SEC Form 4)

      4 - Apollo Medical Holdings, Inc. (0001083446) (Issuer)

      1/24/24 4:31:15 PM ET
      $AMEH
      Professional Services
      Consumer Discretionary
    • SEC Form 3 filed by new insider Kumar Dinesh M.

      3 - Apollo Medical Holdings, Inc. (0001083446) (Issuer)

      1/24/24 4:30:18 PM ET
      $AMEH
      Professional Services
      Consumer Discretionary
    • Vong John was granted 14,352 shares, increasing direct ownership by 293% to 19,253 units (SEC Form 4)

      4 - Apollo Medical Holdings, Inc. (0001083446) (Issuer)

      12/19/23 9:10:18 PM ET
      $AMEH
      Professional Services
      Consumer Discretionary

    $AMEH
    Leadership Updates

    Live Leadership Updates

    See more
    • ApolloMed and BASS Medical Group to Forge a Value-Based Healthcare Partnership

      ALHAMBRA, Calif., Jan. 29, 2024 /PRNewswire/ -- Apollo Medical Holdings, Inc.("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:AMEH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced a strategic long-term partnership with BASS Medical Group, one of the largest multi-specialty medical groups in the Greater San Francisco Bay Area. The partnership will bolster BASS Medical Group's value-based care and operational infra

      1/29/24 8:00:00 AM ET
      $AMEH
      Professional Services
      Consumer Discretionary
    • Akido Appoints Eric Chin as its first Chief Financial Officer As the Company Prepares to Accelerate Growth

      LOS ANGELES, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Akido, a tech-integrated medical network reimagining healthcare from the ground up, announced that Eric Chin has been appointed Chief Financial Officer, effective immediately. Chin will work closely with Akido's co-founders as the company continues to bring its unique blend of AI-powered technology, best-in-class medical services and scalable preventive care programs to new markets across the U.S. Previously, Chin served as Chief Financial Officer at Apollo Medical Holdings (ApolloMed), a publicly traded physician-centric technology-powered healthcare company (NASDAQ:AMEH) that increased reported total revenue from approximately $520 million i

      1/31/23 9:30:00 AM ET
      $AMEH
      Professional Services
      Consumer Discretionary
    • The Oncology Institute Names Mihir Shah as Chief Financial Officer

      CERRITOS, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute of Hope and Innovation (NASDAQ:TOI) today announced the appointment of Mihir Shah as chief financial officer, effective immediately. In this role, Mr. Shah will lead the Accounting, Finance, Revenue Cycle Management, and Investor Relations functions, playing a key role in driving TOI's public company success and executing the strategic growth plan. Mr. Shah succeeds Scott Dalgleish, who will serve as a senior advisor through a transition period. Mr. Shah joins TOI with fifteen years of industry leadership experience across public, private, and not-for-profit organizations. Most recently Mr. Shah served as chief fi

      4/4/22 6:01:00 AM ET
      $AMEH
      $TOI
      Professional Services
      Consumer Discretionary
      Medical/Nursing Services
      Health Care